TABLE 2.
Results (MIC values) of in vitro susceptibility testing of the free extract against C. albicans clinical isolates displaying different mechanisms of azole resistance and against laboratory generated strains with activating mutantions in key genes involved in azole resistance.
| Strain | Description | Overexpressed genes | Extract | Fluconazole |
| 4639 | F449S, T229A (Erg11p substitutions) | MDR1, CDR1 | 7.81 | >64a |
| 4617 | F449S, T229A (Erg11p substitutions) | N/A | 3.9 | 64a |
| 6482 | D116E, K128T, Y132H, D278N, G464S, P230L (Erg11p substitutions) | N/A | 125 | >64b |
| 2440 | V437I (Erg11p substitution) | MDR1, ERG11 | 250 | 64a |
| 3731 | F126L, K143R (Erg11p substitutions) | MDR1 | 500 | >64a |
| 412 | K128T (Erg11p substitution) | N/A | 62.5 | 0.5a |
| TW2 | Clinical isolate (drug resistance observed) | MDR1 | 62.5 | 2c |
| TW3 | Clinical isolate (drug resistance observed) | MDR1 | 62.5 | 8c |
| TW17 | Clinical isolate (multi drug resistance observed) Point mutation: R467K | CDR1, MDR1, ERG11 | 125 | 128c |
| TAC1R34A | Strain with homozygous activating mutation in TAC1 | TAC1, CDR1 and CDR2 | 125 | – |
| MRR1R34A | Strain with homozygous activating mutation in MRR1 | MRR1 and MDR1 | >500 | 3.13d |
| UPC2R14A | Strain with homozygous activating mutation in UPC2 | UPC2 and ERG11 | 15.62 | >256e |
Results for fluconazole are from previous publications using the same standardized methodologies and are provided for comparative purposes. Values are in μg/mL. Fluconazole MIC values from previous reports: aPerea et al., 2001; bLi et al., 2004; cWhite et al., 1997; dSchubert et al., 2011; eFlowers et al., 2012.